CA2294343A1 - Method for optimizing retinal and optic nerve health - Google Patents

Method for optimizing retinal and optic nerve health Download PDF

Info

Publication number
CA2294343A1
CA2294343A1 CA002294343A CA2294343A CA2294343A1 CA 2294343 A1 CA2294343 A1 CA 2294343A1 CA 002294343 A CA002294343 A CA 002294343A CA 2294343 A CA2294343 A CA 2294343A CA 2294343 A1 CA2294343 A1 CA 2294343A1
Authority
CA
Canada
Prior art keywords
adrenergic receptor
beta
composition
carbonic anhydrase
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002294343A
Other languages
English (en)
French (fr)
Inventor
Michael F. Sugrue
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9800449.2A external-priority patent/GB9800449D0/en
Application filed by Individual filed Critical Individual
Publication of CA2294343A1 publication Critical patent/CA2294343A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA002294343A 1997-06-26 1998-06-22 Method for optimizing retinal and optic nerve health Abandoned CA2294343A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US5083597P 1997-06-26 1997-06-26
US60/050,835 1997-06-26
GBGB9800449.2A GB9800449D0 (en) 1998-01-09 1998-01-09 Method for optimizing retinal and optic nerve health
GB9800449.2 1998-01-09
PCT/US1998/013038 WO1999000133A1 (en) 1997-06-26 1998-06-22 Method for optimizing retinal and optic nerve health

Publications (1)

Publication Number Publication Date
CA2294343A1 true CA2294343A1 (en) 1999-01-07

Family

ID=26312917

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002294343A Abandoned CA2294343A1 (en) 1997-06-26 1998-06-22 Method for optimizing retinal and optic nerve health

Country Status (5)

Country Link
EP (1) EP1024810A4 (ja)
JP (1) JP2002506461A (ja)
AU (1) AU740874B2 (ja)
CA (1) CA2294343A1 (ja)
WO (1) WO1999000133A1 (ja)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5948801A (en) * 1998-03-09 1999-09-07 Alcon Laboratories, Inc. Treatment of retinal edema with brinzolamide
US6174524B1 (en) 1999-03-26 2001-01-16 Alcon Laboratories, Inc. Gelling ophthalmic compositions containing xanthan gum
US6261547B1 (en) 1998-04-07 2001-07-17 Alcon Manufacturing, Ltd. Gelling ophthalmic compositions containing xanthan gum
ES2199873T3 (es) 1999-11-01 2004-03-01 Alcon Inc. Composiciones farmaceuticas que contienen un farmaco antibiotico de fluoroquinolona y goma xantan.
PL199321B1 (pl) 2000-07-28 2008-09-30 Alcon Inc Kompozycje farmaceutyczne zawierające tobramycynę i gumę ksantanową
US7109208B2 (en) 2001-04-11 2006-09-19 Senju Pharmaceutical Co., Ltd. Visual function disorder improving agents
JP4948176B2 (ja) 2004-09-28 2012-06-06 千寿製薬株式会社 キサンタンガムおよびアミノ酸を含有する眼科用組成物
PL1911447T3 (pl) 2005-07-11 2010-03-31 Senju Pharma Co Preparat kropli do oczu zawierający gumę ksantanową i terpenoid
US7875271B2 (en) 2006-03-23 2011-01-25 Senju Pharmaceutical Co., Ltd. Ophthalmic composition comprising xanthan gum and glucose
US20100063035A1 (en) 2006-12-15 2010-03-11 Nicox S.A. Carbonic anhydrase inhibitors derivatives
US8222156B2 (en) 2006-12-29 2012-07-17 Lam Research Corporation Method and apparatus for processing a substrate using plasma
JP5305710B2 (ja) * 2008-03-31 2013-10-02 株式会社ニデック ドルゾラミド塩酸塩点眼液

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE9059T1 (de) * 1980-01-28 1984-09-15 Merck & Co. Inc. Ophthalmische kohlensaure anhydrase-inhibitoren enthaltende einlagen zur verringerung intraokularer hypertension.
IE50901B1 (en) * 1980-03-04 1986-08-06 Merck & Co Inc Ophthalmic compositions of carbonic anhydrase inhibitors for topical application in the treatment of elevated intraocular pressure
US5378703A (en) * 1990-04-09 1995-01-03 Alcon Laboratories, Inc. Sulfonamides useful as carbonic anhydrase inhibitors
CA2064160C (en) * 1991-03-27 1998-08-11 Paul J. T. Missel Use of combinations of gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
CA2129037C (en) * 1992-02-21 1998-03-24 Thomas Robert Dean Topical antiglaucoma compositions comprising carbonic anhydrase inhibitors and beta-blockers
AU666957B2 (en) * 1992-08-28 1996-02-29 Alcon Laboratories, Inc. Use of certain anionic surfactants to enhance antimicrobial effectiveness of ophthalmic compositions
US5789435A (en) * 1995-05-22 1998-08-04 Advanced Research And Technology Institute Method to increase retinal and optical nerve head blood flow velocity in order to preserve sight

Also Published As

Publication number Publication date
AU740874B2 (en) 2001-11-15
EP1024810A1 (en) 2000-08-09
EP1024810A4 (en) 2003-06-11
WO1999000133A1 (en) 1999-01-07
JP2002506461A (ja) 2002-02-26
AU8162298A (en) 1999-01-19

Similar Documents

Publication Publication Date Title
US6949518B1 (en) Methods for treating macular degeneration with topiramate
AU715223B2 (en) Ophthalmic compositions containing a carbonic anhydrase inhibitor and xanthan gum
AU740874B2 (en) Method for optimizing retinal and optic nerve health
JPH11504330A (ja) カリウムチャンネル遮断剤の投与により、哺乳動物の眼圧を降下する方法
IE862481L (en) Pharmaceutical compositions of the type which undergo¹liquid-gel phase transition
JPH08509205A (ja) β−シクロデキストリン誘導体及び治療剤を含んだ眼のための局所組成物
JPH10510289A (ja) 眼圧を降下するためのクロリドチャンネル遮断剤の使用
US5049587A (en) Ophthalmic solution for intraocular pressure adjustment
CA2368242A1 (en) Combination therapy for treating glaucoma
CA2247063C (en) Treatment of macular edema
CA2065965C (en) Ophthalmic compositions comprising combinations of a carbonic anhydrase inhibitor and a beta-adrenergic antagonist
WO1993020805A1 (en) Chemical prevention or reversal of cataract by phase separation inhibitors
US5578638A (en) Treatment of glaucoma and ocular hypertension with β3 -adrenergic agonists
US6156785A (en) Method for increasing oxygen tension in the optic nerve and retina
KR100193406B1 (ko) 근시의 예방 및 치료용 조성물
AU746893B2 (en) Method for increasing oxygen tension in the optic nerve and retina
EP2072047A1 (en) Therapeutic agent for opthalmic disease
EP0456988B1 (en) Use of naproxen as mydriatic agent
CA2005753A1 (en) Angiotensin converting enzyme inhibitors in the treatment of glaucoma
JP2002526409A (ja) 光障害性網膜変性疾患処置用組成物

Legal Events

Date Code Title Description
FZDE Dead